Skip to main content
Smart Investors Daily
Boston Scientific Corporation logo

NYSE · BSX

Boston Scientific Corporation

Healthcare · Medical - Devices

$43.64

Down-$0.65 (-1.49%)

Updated Nov 20, 2026, 1:46 AM

SID Score

4.9/10

Composite research score

Smart Money

49/100

Neutral

Market cap
135.98B
P/E ratio
48.75
Dividend yield
0.00%
52-week range
$39.57 – $94.75
Volume
13.25M
Avg. volume
9.87M

Price performance · BSX

BSX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

BSX closed at $43.64 after 20 trading sessions, down 5.15% for the selected period.

Last close
$43.64
Period change
-5.15%
Period low
$41.98
Period high
$46.01
Daily close
View OHLC price history
BSX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$42.50$44.32$42.50$43.6413.25M
Nov 17, 2026$43.28$43.825$43.015$43.0312.91M
Nov 16, 2026$44.63$44.86$43.505$43.6916.11M
Nov 13, 2026$44.69$44.69$44.08$44.349.7M
Nov 12, 2026$45.40$45.60$43.79$44.2011.51M
Nov 11, 2026$44.06$45.8151$43.8692$45.1317.79M
Nov 10, 2026$43.58$44.78$43.40$44.7011.71M
Nov 9, 2026$43.35$44.33$43.04$44.0216.2M
Nov 6, 2026$43.35$43.63$42.69$42.7514.71M
Nov 5, 2026$46.585$46.85$43.895$44.6422.49M
Nov 4, 2026$44.805$46.97$44.76$45.8234.56M
Nov 3, 2026$43.87$44.615$43.21$43.5018.89M
Nov 2, 2026$42.07$44.365$41.90$44.3222.71M
Oct 30, 2026$42.95$43.29$41.725$41.9822.47M
Oct 29, 2026$41.81$43.085$41.675$42.6931.76M
Oct 28, 2026$41.95$43.915$39.57$42.4369.84M
Oct 27, 2026$45.29$45.33$44.855$45.0615.14M
Oct 26, 2026$45.31$46.07$45.125$45.5811.93M
Oct 23, 2026$45.84$46.16$45.215$45.698.77M
Oct 22, 2026$44.72$46.05$44.62$46.0116.4M

Latest BSX news

The latest Smart Investors Daily articles mentioning BSX.

BSX research

Overview

Company profile and research snapshot.

Company profile

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$127.00
Implied upside
—
Analysts
25
BSX recent ratings
DateFirmRatingTarget
Oct 30, 2026TD CowenHold—
Oct 30, 2026BarclaysEqual-Weight—
Oct 29, 2026UBSBuy—
Oct 29, 2026Leerink PartnersOutperform—
Oct 29, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

U.S. Peripheral Liquid Embolic Agents Market Size, Share, Trends and Forecast (2026-2036) Featuring Profiles of Boston Scientific Corp., Terumo Medical Corp. (MicroVention), BlackSwan Vascular (Sirtex Medical), and Instylla

Actionable insights reveal new revenue streams, growth opportunities, competitive strategies, and trends in minimally invasive, image-guided peripheral embolizationDublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "U.S. Peripheral Liquid Embolic Agents Market Size, Share & Trends Analysis Report 2026-2036" has been added to ResearchAndMarkets.com's offering. The U.S. peripheral liquid embolic agents market was valued at USD 99.7 million in 2025 and is projected to increase from USD 110.3 million in 2026

Yahoo · Nov 12, 2026

Boston Scientific (BSX) Is Back In The Spotlight, What Is Driving Attention?

Boston Scientific (BSX) is back in focus after a series of voluntary Class II recalls for its Direxion Torqueable Microcatheter lines, raising questions about quality control, regulatory exposure, and how much risk is now priced into the stock. Recent recall headlines have landed on a stock that was already under pressure. Boston Scientific’s share price is at US$45.13, with a year to date share price return down 52.35% and a 1 year total shareholder return down 56.66%. The 5 year total...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.